Report Overview

The global peptic ulcer drugs market was pegged at US$ 4.27 billion in 2021 and is expected to register a revenue CAGR of 2.6% during the forecast period from 2022 to 2030.

Market Fundamentals                                                                                          

A peptic ulcer is a sore formed in the inner lining of the stomach, damaging the inner lining of the stomach, esophagus, and duodenum. This condition may be caused due to the excess usage of pain-relieving medicines or the infectious bacterium called helicobacter pylori (H. pylori). This medical condition can further lead to severe problems, such as holes in the stomach, and serious damage to the stomach, the lower part of the esophagus, and the upper part of the duodenum. Thus, drugs are used to treat such conditions to avoid such serious complications.

[5654645]

Market Dynamics

The global peptic ulcer drugs market revenue is growing at a rapid pace. It is estimated to show significant revenue growth during the projected period. The revenue growth of this market can be attributed to the increasing prevalence of peptic ulcers, the growing aged population, and the rising advancements in the product. Furthermore, the rising R&D activities, development of a strong product pipeline, and growing adoption of triple therapy are also augmenting the market revenue growth. Additionally, increasing government and private initiatives and funding/investments further fuels the expansion of the peptic drug market. However, challenges, such as the adverse effects of peptic ulcer drugs, and fluctuation in prices, can hinder the market revenue growth to some extent.

Market Ecosystem

The global peptic ulcer drugs market has been analyzed from four perspectives: drug type, ulcer type, distribution channel, and region. 

Peptic Ulcer Drug Market by Drug Type

[7867675]

Based on the drug type, the market has been segmented into antibiotics, h2 antagonist inhibitors, proton pump inhibitors, and others (antacids, a prostaglandin analog, etc.). Antibiotics hold the largest revenue share of the market, thus leading the segment. A peptic ulcer is mainly caused due to helicobacter pylori infection, wherein antibiotics are utilized widely. H. Pylori infection requires triple therapy with two antibiotics and one proton pump inhibitor, thus raising the revenue share of the antibiotics segment. Additionally, proton pump inhibitors hold the second-largest revenue share in the market.

Peptic Ulcer Drug Market by Ulcer Type

Based on the ulcer type, the market has been segmented into a duodenal ulcer, esophageal ulcer, and gastric ulcer. Duodenal ulcer dominates the market with the largest revenue share, because of the increasing prevalence of duodenal ulcer. The risk factors for duodenal ulcers are intensive smoking, higher consumption of alcohol, high stress, a large amount of consumption of spicy and oily food, thus, increasing the occurrence of duodenal ulcers. The gastric ulcer segment holds the second-largest revenue share in the global peptic ulcer drugs market due to the rising prevalence of gastric ulcers.

Peptic Ulcer Drug Market by Distribution Channel

Based on distribution channels,0 the global peptic ulcer drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. Due to large patient footfall, and easy availability of specialty care, the hospital segment holds the dominant position in the global peptic ulcer treatment market. Retail pharmacies maintain the second-largest stake in the market due to the rising prevalence of various respiratory ailments and increased customer demand.

Peptic Ulcer Drug Market by Region

Based on regions the global peptic ulcer drugs market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America leads the global peptic ulcer drugs market with the largest revenue share. It is also expected to maintain its dominance throughout the forecast period. This market's expansion may be ascribed to several elements, including the high frequency of peptic ulcers, the presence of a large geriatric population in the region, and the sophisticated healthcare infrastructure. North America's peptic ulcer drugs market revenue is growing due to rapid expansion in R&D activities, technological progress, and high healthcare spending. The market revenue is also expected to rise due to the approval of innovative products and drugs and a large base of market participants. 

Due to its developed healthcare infrastructure and high healthcare spending, Europe is the second-largest market participant.

A huge geriatric population base, a rapidly evolving healthcare infrastructure, and the rapid adoption of novel technology all are expected to contribute to the Asia Pacific market's rapid revenue growth. The revenue growth in this region is also attributed to increasing medical tourism and higher healthcare expenditure for improved medical facilities in this region.

Competitive Landscape

The prominent players operating in the global peptic ulcer drugs market are: 

• Pfizer Inc.
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Novartis AG
• Mylan Pharmaceuticals Inc.
• Novitium Pharma LLC
• Eisai Co. Ltd.
• Yuhan Corporation
• Zydus Lifesciences Limited
• Boehringer Ingelheim

Strategic Developments

• In Aug 2021, Dr. Reddy's Lab launched a new drug for stomach ulcers (Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules USP, 5 mg/2.5 mg) in the U.S. market. This generic drug was developed to treat colon inflammation, irritable bowel syndrome, and stomach ulcers.

Frequently Asked Questions About This Report